Delivery Order SPE2DB22D3501-SPE2DB26FTL53
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of Ultane 250 ml pen bottles. The contract has a ceiling value of $1,251.38 and is classified as a firm fixed-price delivery order with an ultimate completion date of September 3, 2025. The place of performance is located in Conshohocken, Pennsylvania, which is also the company's corporate headquarters. This award was not set aside for small businesses or...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on September 17, 2025, from the Defense Logistics Agency (DLA) for ULTANE 250 ML in pen bottle format. This firm fixed-price, non-set-aside contract has a ceiling value of $2,310.24 and an ultimate completion date of September 18, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $1,443.90 delivery order to AmerisourceBergen Drug Corp for 250 ml of Ultane in a pen bottle configuration, with an ultimate completion date of October 17, 2025. This is a firm fixed price, competitively awarded order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a competitive delivery order award valued at $1,732.68 from the Defense Logistics Agency's Medical Supply Chain for the supply of Ultane Liquid (250ml, 1 unit). The contract is classified as a firm fixed price delivery order with an ultimate completion date of October 22, 2025. This award was not designated as a set-aside contract, indicating it was competed openly among...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,667.16 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. This contract is for the supply of 4565818463 ULTANE 250 ML PEN BOTTLE 250ML, a pharmaceutical product, with an ultimate completion date of September 17, 2024. The contract is not set aside and serves as a delivery order against a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 between...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,245.66 Firm Fixed Price delivery order (SPE2DX15D1120|SPE2DX25FQ1K4) is for the supply of ULTANE 250 ML PEN BOTTLE 250ML medical products. The award has an ultimate completion date of November 27, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency Medical Supply Chain awarded a $1,443.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ultane Liquid 250mL on September 16, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement running through December 2026. The work will be performed at the contractor's corporate office...
- Amerisourcebergen Drug Corporation, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order valued at approximately $2,917.68 by the Defense Logistics Agency Troop Support Medical (DLA) to supply 250ml bottles of Ultane liquid under the DLA's Prime Vendor Program. Performance will take place at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a period of one day, from August 14 to August 15, 2023. No subcontractors or set aside...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $3,131.09 under a firm fixed-price contract by the Defense Logistics Agency's Medical Supply Chain division. This is a competitively awarded, non-set-aside delivery order with an ultimate completion date of June 30, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- This federal contract award, valued at $1,203.25, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Ultane 250 ML Pen Bottles. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 30, 2025. Amerisourcebergen Drug Corp is the prime contractor, and the contract is not designated as a set-aside. This award is part of a larger Indefinite Delivery Contract (IDC) that...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB26FTL53Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a competitive delivery order valued at $1,155.12 by the Defense Logistics Agency (DLA) for Ultane 250 ml in pen bottle format. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of November 12, 2025, and was competitively awarded without a set-aside designation. This award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government's military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle extending through December 2026. Under this prime indefinite delivery vehicle, AmerisourceBergen supplies a broad range of pharmaceutical products and medical commodities to support Defense Health Agency operations and other federal healthcare systems worldwide. The company's extensive contract portfolio with DLA demonstrates its capability to fulfill federal procurement requirements across multiple therapeutic domains, from specialty medications to generic drugs and medical supplies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 11/10/25 |